My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 532637 | NSE: MANGALAM | Pharmaceuticals & Drugs | Small Cap
1. Is Mangalam Drugs And Organics Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Mangalam Drugs And Organics Ltd is a average quality company.
2. Is Mangalam Drugs And Organics Ltd undervalued or overvalued?
The key valuation ratios of Mangalam Drugs And Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Mangalam Drugs And Organics Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Mangalam Drugs And Organics Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | -4.9% | 3.8% | 12.9% | 19.8% | 22% | 17.1% | -1.2% | 9.9% | 19.8% | 12.9% | - | ||
| Value Creation Index ⓘ | -1.4 | -0.7 | -0.1 | 0.4 | 0.6 | 0.2 | -1.1 | -0.3 | 0.4 | -0.1 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 125 | 123 | 221 | 295 | 303 | 279 | 228 | 282 | 385 | 451 | 370 | ||
| YoY Gr. Rt. % | - | -2.2% | 80% | 33.8% | 2.7% | -7.8% | -18.5% | 24.1% | 36.3% | 17.3% | - | ||
| Adj EPS ⓘ | -9 | -2.3 | 4.7 | 11.2 | 14.5 | 12.3 | -5.1 | 5.2 | 17.7 | 12.4 | 0.8 | ||
| YoY Gr. Rt. % | - | NA | NA | 138.9% | 29.3% | -15.4% | -141.6% | NA | 240.5% | -29.9% | - | ||
| BVPS (₹) ⓘ | 19.9 | 17.6 | 22.3 | 36.9 | 54.2 | 65.6 | 60.4 | 65.7 | 82.6 | 95.1 | 96 | ||
| Adj Net Profit ⓘ | -11.8 | -3.1 | 6.2 | 16.2 | 23 | 19.4 | -8.1 | 8.2 | 28 | 19.6 | 1 | ||
| Cash Flow from Ops. ⓘ | -0.7 | 7.5 | 14 | 21.8 | 42.8 | 24.6 | 21.7 | 30.6 | 27.6 | 25.7 | - | ||
| Debt/CF from Ops. ⓘ | -110.4 | 10.3 | 5.6 | 2.7 | 1.5 | 2.8 | 2.9 | 1.6 | 2.3 | 3.1 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 15.3% | 8.3% | 25.6% | 17.3% | ||||||||
| Adj EPS ⓘ | NA | -3.1% | NA | -29.9% | ||||||||
| BVPS ⓘ | 19 | 11.9 | 16.3 | 15.1 | ||||||||
| Share Price | 37.3% | 0% | 16% | -26.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | -36.8 | -12.4 | 23.6 | 35.5 | 31.2 | 20.5 | -8.1 | 8.2 | 23.8 | 13.9 | 0.8 | |
| Op. Profit Mgn % ⓘ | -3.5 | 7.9 | 9.3 | 12.8 | 15.5 | 16.8 | 4.3 | 8.4 | 15.1 | 10.9 | 6.9 | |
| Net Profit Mgn % ⓘ | -9.4 | -2.5 | 2.8 | 5.5 | 7.6 | 7 | -3.6 | 2.9 | 7.3 | 4.3 | 0.3 | |
| Debt to Equity ⓘ | 2.8 | 3.3 | 2.7 | 1.1 | 0.8 | 0.7 | 0.7 | 0.5 | 0.5 | 0.5 | 0.1 | |
| Working Cap Days ⓘ | 175 | 188 | 152 | 130 | 114 | 130 | 162 | 136 | 126 | 131 | 206 | |
| Cash Conv. Cycle ⓘ | 121 | 123 | 67 | 56 | 58 | 62 | 83 | 47 | 48 | 69 | 41 | |
Sales growth is growing at healthy rate in last 3 years 25.61%
Return on Equity has declined versus last 3 years average to 0.80%
Net Profit has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at -15.37%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.8 | - |
| TTM Sales (₹ Cr.) | 370 | - |
| BVPS (₹.) ⓘ | 96 | - |
| Reserves (₹ Cr.) ⓘ | 136 | - |
| P/BV ⓘ | 1.10 | - |
| PE ⓘ | 131.61 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 95.00 / 172.65 |
| All Time Low / High (₹) | 3.43 / 441.50 |
| Market Cap (₹ Cr.) | 167 |
| Equity (₹ Cr.) | 15.8 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 38.1 |
| Pledged * | 33.57 | 33.57 | 33.57 | 11.59 | 16.88 | 19.98 | 16.97 | 16.22 | 16.65 | 20.93 |
Mangalam Drugs & Organics Limited (Mangalam) is a part of the MangalamGroup promoted by Dhoot family in 1972 as Advent Pharma PrivateLimited with a view to set up a plant for manufacture of organic andinorganic chemicals. Mangalam Drugs & Organics commmenced its business in 1977.
The company manufactures chemicals such as API perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State. It has a multi-product manufacturing facility and a in-house Research and Development (R&D) Base.
The Company has a diversified product range having synergies in operations and substantial economies of scale. It is amongst the top three manufacturers in India in almost all the products that it manufactures.
Today Mangalam Drugs & Organics enjoys a very strong brand name in the domestic market. It has over two decades of experience in the industry with a very wide and satisfied customer base.
The company has a state of art multi-product manufacturing facilitiesat Vapi in Gujarat and Sangamner in Maharashtra for production of bulkdrugs perfumery chemicals inorganic chemicals and disperse dyesintermediaries with a strong in-house Research and Development base.
Product range of the company includes:
Active Pharma Ingredients (API)
API Under Development
Prefumery / Specialty Chemicals
Disperse Dye Intermediates
Achievements/ recognition:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
